SCHEMBL932780

SCHEMBL932780

O=c1cnc2cc(Br)cnc2[nH]1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 4/20 0.55
RPS6KA3 P51812 2/20 0.55
GSK3A P49840 2/20 0.55
GSK3B P49841 2/20 0.55
AURKA O14965 2/20 0.55
JAK2 O60674 2/20 0.55
PRKD3 O94806 2/20 0.55
MAP4K4 O95819 2/20 0.55
FGFR1 P11362 2/20 0.55
FLT1 P17948 2/20 0.55
KDR P35968 2/20 0.55
CLK2 P49760 2/20 0.55
CDK5 Q00535 2/20 0.55
MAP4K2 Q12851 2/20 0.55
TAOK1 Q7L7X3 2/20 0.55
AURKB Q96GD4 2/20 0.55
CLK4 Q9HAZ1 2/20 0.55
DAPK3 O43293 1/20 0.55
PAK4 O96013 1/20 0.55
ABL1 P00519 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4302243 0.77 RPS6KA3 (0.40) DYRK1ARPS6KA3GSK3AGSK3BAURKA
SCHEMBL1252408 0.72 AURKA (0.49) DYRK1ARPS6KA3GSK3AGSK3BAURKA
SCHEMBL782851 0.72 RPS6KA3 (0.64) DYRK1ARPS6KA3GSK3AGSK3BAURKA
SCHEMBL30405858 0.72 AURKA (0.49) DYRK1ARPS6KA3GSK3AGSK3BAURKA
SCHEMBL18739119 0.72 RPS6KA3 (0.39) DYRK1ARPS6KA3GSK3AGSK3BAURKA
SCHEMBL32683988 0.72 ABL1 (0.45) DYRK1ARPS6KA3GSK3AGSK3BAURKA
SCHEMBL934055 0.71 DYRK1A (0.52) DYRK1ARPS6KA3GSK3AGSK3BAURKA
SCHEMBL29470857 0.71 DYRK1A (0.52) DYRK1ARPS6KA3GSK3AGSK3BAURKA
SCHEMBL4146190 0.71 SMN1; SMN2 (0.55) DYRK1ARPS6KA3GSK3AGSK3BAURKA
SCHEMBL481676 0.71 DYRK1A (1.00) DYRK1ARPS6KA3GSK3AGSK3BAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10100053-B2 Process for the preparation of 8-(4-aminophenoxy)-4H-pyrido[2,3-b]pyrazin-3-one derivatives CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-10-16 US disclosed
EP-3074395-B1 PROCESS FOR THE PREPARATION OF 8-(4-AMINOPHENOXY)-4H-PYRIDO[2,3-B]PYRAZIN-3-ONE DERIVATIVES CANCER RESEARCH TECH LTD (GB) 2018-08-22 EP disclosed
US-20170298065-A1 PROCESS FOR THE PREPARATION OF 8-(4-AMINOPHENOXY)-4H-PYRIDO[2,3-B]PYRAZIN-3-ONE DERIVATIVES CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2017-10-19 US disclosed
US-9708317-B2 Process for the preparation of 8-(4-aminophenoxy)-4H-pyrido[2,3-B]pyrazin-3-one derivatives CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2017-07-18 US disclosed
US-20160297814-A1 PROCESS FOR THE PREPARATION OF 8-(4-AMINOPHENOXY)-4H-PYRIDO[2,3-B]PYRAZIN-3-ONE DERIVATIVES OXY SCIENTIFIC LIMITED (GB) 2016-10-13 US disclosed
EP-3074395-A1 PROCESS FOR THE PREPARATION OF 8-(4-AMINOPHENOXY)-4H-PYRIDO[2,3-B]PYRAZIN-3-ONE DERIVATIVES Cancer Research Technology Ltd (GB) 2016-10-05 EP disclosed
WO-2015075482-A1 PROCESS FOR THE PREPARATION OF 8-(4-AMINOPHENOXY)-4H-PYRIDO[2,3-B]PYRAZIN-3-ONE DERIVATIVES CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2015-05-28 WO disclosed
US-20120178742-A1 METABOTROPIC GLUTAMATE RECEPTOR MODULATORS MERZ PHARMA GMBH & CO. KGAA (DE) 2012-07-12 US disclosed
US-20110112100-A1 Hepatitis C Virus Inhibitors PFIZER INC. 2011-05-12 US disclosed
US-20110112100-A1 Hepatitis C Virus Inhibitors PFIZER INC. 2011-05-12 US disclosed
US-20110112100-A1 Hepatitis C Virus Inhibitors PFIZER INC. 2011-05-12 US disclosed
WO-2011004276-A1 HEPATITIS C VIRUS INHIBITORS PFIZER LIMITED (GB) 2011-01-13 WO disclosed
WO-2011004276-A1 HEPATITIS C VIRUS INHIBITORS PFIZER LIMITED (GB) 2011-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178742-A1 METABOTROPIC GLUTAMATE RECEPTOR MODULATORS GRM5, GRIK5, GRM1 DYRK1A 2272/4885RPS6KA3 2892/4885GSK3A 3557/4885
US-10100053-B2 Process for the preparation of 8-(4-aminophenoxy)-4H-pyrido[2,3-b]pyrazin-3-one derivatives PAM, PDXK, GRHPR DYRK1A 2910/4885RPS6KA3 2518/4885GSK3A 3737/4885
US-20110112100-A1 Hepatitis C Virus Inhibitors HAVCR2, SLC10A1, HCCS DYRK1A 4837/4885RPS6KA3 1208/4885GSK3A 590/4885
US-20170298065-A1 PROCESS FOR THE PREPARATION OF 8-(4-AMINOPHENOXY)-4H-PYRIDO[2,3-B]PYRAZIN-3-ONE DERIVATIVES TDO2, HPD, PDXK DYRK1A 2009/4885RPS6KA3 3161/4885GSK3A 3206/4885
US-20160297814-A1 PROCESS FOR THE PREPARATION OF 8-(4-AMINOPHENOXY)-4H-PYRIDO[2,3-B]PYRAZIN-3-ONE DERIVATIVES PAM, PDXK, GRHPR DYRK1A 2910/4885RPS6KA3 2518/4885GSK3A 3737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.